ALS advocate seeks a cure by 2021

CBS News - 6 days ago
"The ALS Association was the...

Excerpts from Supreme Court Same-Sex Marriage Ruling

Santa Barbara Independent - 4 days ago
To them, it would demean a...

Expanding access to experimental drugs

Lexology (registration) - 4 weeks ago
Accordingly, more sophisticated...

California bill gives terminally ill patients right to try experimental drugs

Daily Democrat - 1 week ago
SACRAMENTO >> Not long after...

The mayor vs the mogul

Politico - 2 weeks ago
Doctoroff's father and uncle...

Copy Me If You Can! Part 1

Genetic Engineering & Biotechnology News - 2 weeks ago
Steve Perrin, Ph.D., CEO and CSO,...

Sinclair vote of confidence, zippy growth fuel ZypMedia rebrand

L.A. Biz - 3 weeks ago
When I first talked to ExtendTV...

NBA: For Cavs, Warriors

and Jazz - 4 weeks ago
Commissioner Adam Silver has said...

Washington Healthcare Update

JD Supra (press release) - 3 weeks ago
Five bills were passed concerning...

ALS Drug Access Debated

The Scientist - 3 months ago
In addition to the Phase 2...

News via Google. See more news matching 'als expanded access'

 

Expanded Access

Bringing Research and Patients Together

Our Expanded Access platform is meant to do two things:

  1. Empower patients with access to new treatments that are in clinical research.
  2. Empower further research with clinical data from those patients.

For someone with a quick-killer disease, participating in clinical research may be the only way to access a new medicine that might help him live longer.  He may be willing to accept some uncertainty, considering the alternative.  So for patients, there’s a lot of overlap between treatment exploration and research.

But what about patients who cannot get into clinical trials?  Can they still take part in research and explore investigational treatment?

Yes, they can, but only through what are called Expanded Access programs (EAPs).  These are meant to include a much broader group of patients than traditional clinical trials, sometimes exclusively those patients who don’t meet clinical trial enrollment criteria or who otherwise cannot get into trials.

ALS-ETF is bringing a new kind of Expanded Access to the ALS community, to make a groundbreaking impact in the treatment landscape for patients as well as the research that’s powered by patient data.

Learn more about Expanded Access programs here.

Learn more about our research goals here.